27 results
Thumbnail

- D3.164 - Safety and Efficacy of VIT against Wasp Venom in Patients Older than 60 Years

Thumbnail

- D3.165 - Consistent long term benefit of allergen immunotherapy in patients with allergic rhinitis

Thumbnail

- D3.166 - The mental health of adolescent patients with cat allergy improves with rapid dosing of depigmented cat allergoids

Thumbnail

- D3.167 - Allergoids: Characterising Identity Pre- and Post- Modification Using Compendial and Novel Methods

Thumbnail

- D3.169 - Advantage of IgG reactivity testing for the analytical quantification of allergoids

Thumbnail

- D3.172 - Аllergen-specific immunotherapy in patients with allergic rhinitis

Thumbnail

- D3.173 - Nationwide pivotal registry study on house dust mite immunotherapy in allergic rhinitis patients with or without asthma in China (NAVIGATOR)

Thumbnail

- D3.174 - Comparative analysis of extracts from Cupressus arizonica and Juniperus ashei pollens

Thumbnail

- D3.175 - Tumor Necrosis Factor Receptor 2 (TNFR2) is crucial for the efficacy of Allergen-Specific Immunotherapy in a Pre-clinical Murine Model

Thumbnail

- D3.176 - The value of TNF and IL1RN genes in predicting the clinical efficacy of SCIT in children with asthma

Thumbnail

- D3.177 - Potency of Dermatophagoides spp SLIT tablet compared to US standardized mite in ID testing

Thumbnail

D3.170 - Effectiveness and Safety Study of Subcutaneous Immunotherapy for Respiratory Allergy to Dermatophagoides and Lepidoglyphus Destructor

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"